Back to all events
Datum
8 September 2026 10:00–11:00
Organized by
QbD Group
Event type News labels / tags
Medical biotech
Software & IT

Webinar - Regulatory Evolution: What AI Means for GMP Manufacturing

What AI Means for GMP Manufacturing

A practical, inspector-informed look at what deploying AI in GMP-regulated environments really means: validation, human oversight, auditability, explainability, and the ongoing monitoring that traditional CSV was never designed for.

AI is moving from proof of concept into GMP-regulated manufacturing, and inspectors have noticed. Recent sessions with the FDA and UK MHRA have flagged the same pitfalls again and again: models that drift once deployed, unclear human oversight, and validation approaches built for static computerized systems being stretched to cover something they were never designed for.

This webinar cuts past the theoretical AI hype and focuses on what deploying an AI system in a GMP environment actually looks like in practice — what inspectors are currently examining, why AI needs deeper ongoing monitoring than traditional computerized systems, and the reminder that existing GMP requirements (user access, audit trails, change control) still fully apply to AI-enabled tools.

You do not need to be an AI expert to attend. If you own quality, validation, or regulatory compliance in a pharma or biotech manufacturing site, this session gives you a practical framework to prepare for the next wave of AI-related inspection findings.

What you'll learn

  • What FDA and MHRA inspectors are currently looking at when AI shows up in a GMP environment
  • Why AI systems require deeper, continuous monitoring compared with traditional computerized systems
  • How to apply existing GMP requirements (user access, audit trails, change control, data integrity) to AI-enabled tools
  • How risk-based validation (CSV / CSA) needs to evolve to handle model drift, bias, and continuous improvement

 

Speakers

Jan Appelmans, Senior Consultant Software Services, QbD Group

Jan supports pharma and biotech manufacturers on computerized system validation, digitalization projects, and the compliance implications of new technologies — including AI — entering GMP environments.

 

Elias Muys, Associate Consultant, QbD Group

Elias has a background in bioscience engineering and an advanced master in AI as well as with hands-on experience in pharmaceutical qualification and validation. He explores practical ways to use AI and automation to streamline everyday tasks while keeping the requirements of regulated environments in mind.

Upcoming events

-
Medical Device Seminar Series 2026 – The EU Medical Device Regulation in Motion: Regulators, Industry and the Road Ahead